About atossa therapeutics - ATOS
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
ATOS At a Glance
Atossa Therapeutics, Inc.
1448 NW Market Street
Seattle, Washington 98107
| Phone | 1-206-588-0256 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -34,770,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATOS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.937 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.937 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ATOS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,483,571.429 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ATOS Liquidity
| Current Ratio | 5.526 |
| Quick Ratio | 5.526 |
| Cash Ratio | 5.016 |
ATOS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -56.057 |
| Return on Equity | -62.745 |
| Return on Total Capital | -88.354 |
| Return on Invested Capital | -62.745 |
ATOS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |